Bactericidal Activity of Ciprofloxacin Against Amikacin- and Cefotaxime-resistant Gram-negative Bacilli and Methicillin-resistant Staphylococci

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1986 Jun 1

PMID 2942105

Citations 8

Authors

M S Simberkoff

J J Rahal Jr

Affiliations

Soon will be listed here.

Abstract

The MICs and MBCs of ciprofloxacin were determined for clinical isolates of antibiotic-resistant aerobic bacteria. Decreased susceptibility to ciprofloxacin of cefotaxime- and amikacin-resistant Serratia marcescens and amikacin-resistant Pseudomonas aeruginosa strains were noted. The data suggest that ciprofloxacin susceptibility should be carefully monitored in treating patients with hospital-acquired bacterial infections.

Citing Articles

Occurrences and Characterization of Antibiotic-Resistant Bacteria and Genetic Determinants of Hospital Wastewater in a Tropical Country.

Le T, Ng C, Chen H, Yi X, Koh T, Barkham T Antimicrob Agents Chemother. 2016; 60(12):7449-7456.

PMID: 27736769 PMC: 5119029. DOI: 10.1128/AAC.01556-16.

Comparison of in vitro activity of quinolone antibiotics and vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus by time-kill kinetic studies.

Foster J, Lentino J, Strodtman R, DiVincenzo C Antimicrob Agents Chemother. 1986; 30(6):823-7.

PMID: 3643771 PMC: 180601. DOI: 10.1128/AAC.30.6.823.

Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Monk J, Price A, Benfield P, Todd P, Ward A Drugs. 1988; 35(4):373-447.

PMID: 3292209 DOI: 10.2165/00003495-198835040-00003.

Activity of ciprofloxacin against multiply resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, and group JK corynebacteria.

Venezio F, Tatarowicz W, DiVincenzo C, OKeefe J Antimicrob Agents Chemother. 1986; 30(6):940-1.

PMID: 3101589 PMC: 180624. DOI: 10.1128/AAC.30.6.940.

Fluoroquinolone antimicrobial agents.

Wolfson J, Hooper D Clin Microbiol Rev. 1989; 2(4):378-424.

PMID: 2680058 PMC: 358131. DOI: 10.1128/CMR.2.4.378.

References

Wise R, Andrews J, Edwards L . In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983; 23(4):559-64. PMC: 184701. DOI: 10.1128/AAC.23.4.559. View

Fass R . In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother. 1983; 24(4):568-74. PMC: 185375. DOI: 10.1128/AAC.24.4.568. View

Chin N, Neu H . Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984; 25(3):319-26. PMC: 185508. DOI: 10.1128/AAC.25.3.319. View

Eliopoulos G, Gardella A, Moellering Jr R . In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother. 1984; 25(3):331-5. PMC: 185510. DOI: 10.1128/AAC.25.3.331. View

Barry A, Jones R, Thornsberry C, Ayers L, Gerlach E, Sommers H . Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob Agents Chemother. 1984; 25(5):633-7. PMC: 185603. DOI: 10.1128/AAC.25.5.633. View

Schiff J, Small G, Pennington J . Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother. 1984; 26(1):1-4. PMC: 179903. DOI: 10.1128/AAC.26.1.1. View

Gonzalez M, Uribe F, Moisen S, Fuster A, Selen A, Welling P . Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother. 1984; 26(5):741-4. PMC: 180005. DOI: 10.1128/AAC.26.5.741. View

Brumfitt W, Franklin I, Grady D, Hamilton-Miller J, Iliffe A . Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother. 1984; 26(5):757-61. PMC: 180008. DOI: 10.1128/AAC.26.5.757. View

Levine J, Maslow M, Leibowitz R, Pollock A, Hanna B, Schaefler S . Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use. J Infect Dis. 1985; 151(2):295-300. DOI: 10.1093/infdis/151.2.295. View

10.

Sanders C, Sanders Jr W, Goering R, Werner V . Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother. 1984; 26(6):797-801. PMC: 180026. DOI: 10.1128/AAC.26.6.797. View

11.

Simberkoff M, Lukaszewski M, Cross A, Al-Ibrahim M, Baltch A, Smith R . Antibiotic-resistant isolates of Streptococcus pneumoniae from clinical specimens: a cluster of serotype 19A organisms in Brooklyn, New York. J Infect Dis. 1986; 153(1):78-82. DOI: 10.1093/infdis/153.1.78. View

12.

Sanders C, Watanakunakorn C . Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens. J Infect Dis. 1986; 153(3):617-9. DOI: 10.1093/infdis/153.3.617. View

13.

Eron L, Harvey L, Hixon D, Poretz D . Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria. Antimicrob Agents Chemother. 1985; 28(2):308-10. PMC: 180237. DOI: 10.1128/AAC.28.2.308. View

14.

Gutmann L, Williamson R, Moreau N, Kitzis M, Collatz E, Acar J . Cross-resistance to nalidixic acid, trimethoprim, and chloramphenicol associated with alterations in outer membrane proteins of Klebsiella, Enterobacter, and Serratia. J Infect Dis. 1985; 151(3):501-7. DOI: 10.1093/infdis/151.3.501. View

15.

Crook S, Selkon J, McLardy Smith P . Clinical resistance to long-term oral ciprofloxacin. Lancet. 1985; 1(8440):1275. DOI: 10.1016/s0140-6736(85)92343-8. View

16.

Gordin F, Hackbarth C, SCOTT K, Sande M . Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs. Antimicrob Agents Chemother. 1985; 27(4):452-4. PMC: 180073. DOI: 10.1128/AAC.27.4.452. View

17.

Roberts C, Batten J, Hodson M . Ciprofloxacin-resistant Pseudomonas. Lancet. 1985; 1(8443):1442. DOI: 10.1016/s0140-6736(85)91862-8. View

18.

Rella M, Haas D . Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes. Antimicrob Agents Chemother. 1982; 22(2):242-9. PMC: 183719. DOI: 10.1128/AAC.22.2.242. View

19.

Ramirez C, Bran J, Mejia C, Garcia J . Open, prospective study of the clinical efficacy of ciprofloxacin. Antimicrob Agents Chemother. 1985; 28(1):128-32. PMC: 176323. DOI: 10.1128/AAC.28.1.128. View

20.

Strunk R, Gratz J, Maserati R, Scheld W . Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis. Antimicrob Agents Chemother. 1985; 28(3):428-32. PMC: 180267. DOI: 10.1128/AAC.28.3.428. View